Converting Liver Tumors into Low-Oxygen Environment to Activate Drug to Drive Cell Death with Dr. Ray Lee Teclison TRANSCRIPT
Download PDFNov 14, 2022
Dr. Ray Lee is the CEO of Teclison, focused on overcoming the limitations of existing immunotherapy for treating liver cancer in part caused by the fact that the liver is a highly immunotolerant organ. The key is to make the tumor a low-oxygen environment and delivering a drug that only works on the tumor.
Ray...
Nov 14, 2022
Dr. Ray Lee is the CEO of Teclison, focused on overcoming the limitations of existing immunotherapy for treating liver cancer in part caused by the fact that the liver is a highly immunotolerant organ. The key is to make the tumor a low-oxygen environment and delivering a drug that only works on the tumor.
Ray...
Using Oncolytic Viral Immunotherapy to Kill Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics TRANSCRIPT
Download PDFSep 19, 2022
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of...
Using Oncolytic Viral Immunotherapy to Kill Solid Tumors with Dr. Paul Peter Tak Candel Therapeutics
Sep 19, 2022
Dr. Paul Peter Tak is the CEO and President of Candel Therapeutics, developing innovative immunotherapies for patients with solid tumors that are difficult to treat, like brain cancer, pancreatic cancer, prostate cancer, and non-small cell lung cancer. This approach induces cell death in cancer cells at the site of...
Using Antibodies from Memory B Cells to Restore Immune Response to Autoimmune Oncologic and Infectious Diseases with Matthew Robinson Immunome TRANSCRIPT
Download PDFJul 19, 2022
Matthew Robinson is the Senior Vice President of R&D at Immunome, which is leveraging the information in memory B cells to target antibody therapeutics to kill tumor cells.
Matthew explains, "At Immunome, we believe that the antibodies that these B cells are making have an ability to see the different types of tumor...